targetmol bioactive compound library (TargetMol)
Structured Review
Targetmol Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 107 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pm42456852-186-14-14
Average 97 stars, based on 107 article reviews
Images
Related Articles
Activity Assay:Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Disruption:Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Concentration Assay:Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Control:Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Analysis:Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol |
